Amgen cutbacks don’t let up

Thousand Oaks-based biotech giant Amgen has announced another round of layoffs. This time, however, they won’t affect its local headquarters.
The reorganization will result in about 300 jobs lost from its Onyx Pharmaceuticals facilities in San Francisco.
Amgen purchased Onyx Pharmaceuticals, which produces cancer drugs, for $9.7 billion in October 2013.
In a companywide March 9 memo, Amgen chair/CEO Bob Bradway said Amgen will consolidate its commercial and development oncology work...

Oops! An active online subscription is required to access this content.

Please login below or Subscribe today!